Telix Pharmaceuticals Ltd (ASX: TLX) saw its shares soar 5.04% during intraday trading on Friday, marking a significant upward movement for the biopharmaceutical company.

The surge follows the company's resubmission of its New Drug Application to the U.S. FDA for TLX101-Px, an imaging agent for glioblastoma, with new data addressing prior feedback and supporting approval. This regulatory progress in a high-need area with limited competition represents a potential major growth driver for the company.

Additionally, Telix recently reported strong financial performance with full-year revenue reaching US$803 million, representing 56% year-on-year growth, and provided optimistic guidance for the current year. The company also benefits from overwhelmingly positive analyst sentiment, with all 16 covering analysts rating the stock as a buy or strong buy.